Make the most of your digital experience
Tailor Your Agenda – with sessions spanning across multiple days, design your own agenda based on who you want to hear from and what will be most useful to your business.
Get More Involved – virtual events offer many more interactive opportunities than live events; participate in live polls, live Q&A and live panel discussions – helping you build your personal brand and your business connections.
Improved Audience Visibility – you can see exactly who is registered to attend the event and when they’re online – make that valuable connection in real-time!
On-Demand Content – missed a session or couldn’t tune in that day? That’s fine, sessions will be available to listen to for 2 months post event. That also means you can listen to your favourite speaker multiple times.
High Quality Speakers – this doesn’t change, whether we run a live event or a virtual one, we recruit industry leading, insightful speakers to inspire.
More Networking Opportunities – do you sometimes miss the one person you were hoping to meet at live events? With virtual events you can instant message them, reserve a time in their diary, and email them.
Save Time & Money – tune into an event from the comfort of your own home, no need to travel overseas, spend time away from loved ones and spend your company’s money! This makes networking and knowledge sharing much more cost efficient.
Increased Content – we can run more sessions at one time without the constraints of venue capacities, meaning we can provide you with more valuable content in one go.
Business Development Opportunities – for those looking to partner on the virtual events, there’s lots of session formats that will place you at the centre of the conversations you need to have, including but not limited to; topic specific roundtables, keynote panels, ask the expert chat rooms and more. Talk to our team to find out more [email protected].
Insights – using analytics, we can help you benchmark, to stay ahead of industry trends. We can also share audience insights on job titles, seniority and geography, so you know your networking with the right connections to match your business needs.
Why Attend
Onco Cell Therapy Summit (OCTS), formerly the CAR-T Congress, is an event that brings industry together to share novel research, manufacturing techniques and regulatory best practice. Each session of OCTS 2020 is dedicated to translating your novel data assets & IP into commercially viable oncological therapies.
OCTS is a 4-track event and whilst bringing together the key decision makers for CAR-T therapies, this year’s event will have an added focus on the ground breaking science that is driving the surge of interest in harnessing alternative cell therapies in cancer treatments.
With 2 of our tracks comprised of research on CAR-T and alternative cell therapies, the other pillar in rolling out these therapies is increasing the affordability of the treatments. The other two tracks will delve into best practice in commercialization and manufacturing of immuno-oncological cell therapies.
Each day of the summit will conclude in plenary room panels that spin out into bespoke roundtable discussions to break down the key challenges in major topics to R&D, manufacturing and commercialization.
WHO WILL BE THERE
Network with industry experts from:
- Big pharma and biotech
- Cell Therapy Academics and clinicians
- Process standardisation - technology/services
- Logistics companies - cell storage/transport
- Service providers - CRO’s, Consultants, Government
Past attendees include:
TESTIMONIALS
The Agenda
Following the third annual CAR-T Congress earlier this year, we recognized a need for more content, covering regulation, alternative cell therapies and commercialization. Introducing the Onco Cell Therapy Summit (OCTS), dedicated to translating the emerging novel data from leading academia and innovating biotechs into commercially viable therapies.
Join us to take a deep dive into the research on solid tumors and “off the shelf” therapies that are defining the direction for oncological cell therapy development pipelines. Each day of the congress will conclude in plenary room panels that spin out into bespoke roundtable discussions to break down the key challenges in major topics to R&D, manufacturing and commercialization.
New for this year
• 4 tracks focusing on: CAR-T R&D, Alternative Cell Therapies, Vein-to-Vein
Commercialization, Regulation and Safety;
• More networking across the industry, where you can organise private 1-2-1 virtual meetings.
Download Agenda
The Speakers
Carl June
Adlai Goldberg
Keenly focused on capturing opportunities and managing impacts created by the digital megatrend for the life sciences clients.
As EY Global Life Sciences Digital, Social and Commercial Innovation Leader, Adlai is focused on developing the necessary digital infrastructure to support emerging, next-generation forms of individualized therapies to tackle cancer and rare diseases.
Having a keen interest in different cultures, he has chosen to spend his career living and working around the world in many markets including Japan, Thailand, Hong Kong, Indonesia, Ukraine, Russia and Switzerland.
With more than 28 years of professional experience in media, communications and consulting to his credit, Adlai helped establish EY global social media services and analytics hub. Additionally, he has also helped launch the world’s first interactive television platform in Hong Kong.
Adlai earned an MBA in Marketing and Real Estate from Southern Methodist University and a BS in Accounting from Metropolitan State College. How Adlai is building a better working world “I have been blessed with two opportunities to make important contributions to this world. First, I helped directly support the reconstruction and rehabilitation of communities affected by the tsunami in 2004 that hit Indonesia, Sri Lanka and Thailand.
For three years, I worked with donors and helped nongovernmental organizations manage their financial resources in order to provide the greatest support possible. I also design and help manage a tsunami commemoration program on behalf of the Republic of Indonesia.
Second, I helped design the necessary digital infrastructure needed to support emerging individualized therapies that may, one day, help cure cancer and rare diseases.”
Knut Niss
Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr. Niss was Senior Technical Project Leader at Novartis’ cell therapy manufacturing facility in Morris Plains, New Jersey, where he directed the transfer and implementation of the CTL019 process from Penn to Novartis. He also served as Senior R&D Program Manager at EMD Millipore, where he established processes for the large-scale expansion of adult and pluripotent stem cells. Dr. Niss began his career in senior research positions in Pfizer’s Regenerative Medicine and Immunology groups. He holds a Ph.D. in molecular biology from Humboldt University of Berlin, and an M.S. in microbiology from the University of Göttingen in Germany. Dr. Niss completed his postdoctoral research at Boston Children’s Hospital and the Dana-Farber Cancer Institute.
Peter Emtage
Dr. Emtage currently serves as Chief Scientific Officer at Cell Design Labs, Inc. (CDL). Prior to joining CDL, he was Vice President of Synthetic Immunology at Intrexon Corporation and was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune. At Medimmune, Dr. Emtage designed and implemented a comprehensive immune therapy cancer strategy. He has over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Dr. Emtage holds a B.S. and M.S. in Molecular Biology and Genetics from the University of Guelph and received his Ph.D. in Molecular Virology, Immunology and Inflammation at McMaster University. At the beginning of his career, he also was a post-doctoral fellow at the National Institutes of Health and held roles at Aventis Pasteur and Harvard Medical School.
Dr. Christina Coughlin
Caron Jacobson
Orlando Serani
As of May 2018, Orlando leads the program strategy for the recently announced Chimeric Antigen Receptor T-Cells therapeutic area. This includes digital strategies, supply chain network design, and supply chain capability development for this therapy platform, currently targeted as a last line of defense for multiple myeloma.
Previously, Orlando was Vice President, Information Technology, Customer and Logistics Services: the logistics and customer services organization which serves all Johnson & Johnson businesses globally. Additionally, he also led the technology organization of the Consumer Medical Devices supply chain, including diabetes, contact lenses, and vision surgery products and services.
Orlando began his career with the Johnson & Johnson Consumer business in Italy in 1988. After a Foreign Service National assignment with the United States Information Agency in Rome, Italy from 1990 until 1992, he rejoined Johnson & Johnson’s Ortho-Clinical Diagnostics, where he held diverse positions in R&D, Sales and Marketing, and IT. In 2010, as part of the announcement of the Johnson & Johnson enterprise supply chain, he led the development of strategies to further establish and create new business services including safe and secure supply chain (i.e. anti-counterfeit, serialization, track and trace), enterprise-wide internal and external technology standards (enterprise master data, GS1, UDI, RFID), and new channel management strategies (ecommerce, demand sensing, distribution and transportation optimization).
Orlando holds a Bachelor of Science in Electrical Engineering from Rutgers University. He has been actively involved in several industry forums focused to the development and adoption of industry standards, including the development and adoption of the ISBT-128 transfusion medicine, including current membership in the US GS1 technical advisory group. He is a member of the program advisory board for the graduate supply chain program of Fairleigh Dickinson University, Silberman College of Business. He is an active speaker for the South Asian Professional Network Association (SAPNA) and Hispanic Organization for Leadership and Achievement (HOLA) enterprise groups, and a sponsor for the African American Leadership Council (AALC). He is active in his community, especially on activities focused on raising awareness of social and health issues.
Sarah Dye
As Vice President of Oncology and Specialty Pharmaceuticals with Optum’s Medical Benefit Management division, Sarah has responsibility for a comprehensive solution set that includes the Cancer and Specialty Guidance Programs. Sarah is passionate about these complicated conditions and how Optum can help ensure consumers receive quality care and support services to help them navigate a complicated system.
Sarah joined UnitedHealth Group in 2003 and held several other roles including leading Operations and Affordability with Optum International where she focused entirely on the Brazil health care market. Prior to Optum International, Sarah was Principal at UnitedHealth Group Ventures where she analyzed the market to identify new investment opportunities designed to create disruptive, positive change in the health care system.
Across her roles, Sarah uses her engineering training to perform root cause analysis to identify systemic issues in the health care and ultimately design new products to address these issues. She successfully developed and launched new products in oncology, women’s health and orthopedics.
Sarah holds a bachelor’s degree in industrial engineering from Iowa State University.
Dr. Matthew Spear
Peggy Sotiropoulou
Shirley O'Dea
David C. Rhew, MD
Dr. David C. Rhew is the Global Chief Medical Officer (CMO) and Vice-President (VP) of Healthcare for Microsoft. He is the Chairman of the Health and Fitness Technology Division for the Consumer Technology Association and serves on CTA’s Board of Industry Leaders. He co-holds six U.S. technology patents that enable authoring, mapping, and integration of clinical decision support into the electronic health record. David is currently an Adjunct Professor at the Stanford University School of Medicine.
Dr. Rhew received his Bachelors of Science degrees in computer science and cellular molecular biology from the University of Michigan. He received his MD degree from Northwestern University and completed internal medicine residency at Cedars-Sinai Medical Center. He completed fellowships in health services research at Cedars-Sinai and infectious diseases at the University of California, Los Angeles.
He has served as CMO and VP for Samsung; Senior Vice-President and CMO at Zynx Health Incorporated; clinician/researcher in the Division of Infectious Diseases at the VA Greater Los Angeles Healthcare System; and Associate Clinical Professor of Medicine at UCLA. Dr. Rhew has served on the National Quality Forum’s (NQF) Executive Committee for Consensus Standards and Approval.
Neehar Bhatia
Neehar Bhatia, Ph.D. is Associate Director of Process Development and Manufacturing at Laboratory of Cell and Gene Medicine (LCGM), Stanford University. Dr. Bhatia received a Ph.D. in Biochemistry from the Central Drug Research Institute, India. Dr. Bhatia is responsible for development and manufacturing of cGMP compliant cell and gene therapy products at LCGM. Dr. Bhatia oversees manufacturing for multiple projects such as CD19/CD22 bi-specific CAR-T and other T cell based therapies, CD34 HSPC transplant and manufacturing of AAV6 for gene correction in HSPC. Dr. Bhatia has lead multiple projects which include banking of ESCs, iPSCs, MSCs and iPSC derived differentiated cells, development of GMP process for translational projects and manufacturing cell therapies for Phase I/II clinical trials. Dr. Bhatia has also lead efforts in quest for serum-free chemically defined culture medium for MSCs and development of platform technology for AAV production. Dr. Bhatia’s focus is on development of cGMP compliant manufacturing process for “bench to bedside” cell and gene therapies.
Fred Koller, Ph.D.
Christine E. Brown
Steven Feldman
Dr. Steven A. Feldman was a Staff Scientist and Director of the Vector Production Facility at Surgery Branch, NCI for the past twelve years. Dr. Feldman’s group was responsible for the development, characterization, and manufacturing of the viral vectors used in gene therapy clinical trials at the Surgery Branch. Recently, Dr. Feldman joined the Stanford Center for Cancer Cell Therapy as Director of Manufacturing and Process Science where he will take a lead role in the development and manufacture of viral vectors and novel cell therapies for the treatment of cancer.
Bob Valamehr, PhD MBA,
Seshu Tyagarajan
Ali Mohamed
Paul Lammers
Steve Lynum
Professor David Miklos
Dr. Leonard Lichtenfeld
John T. Elliott
Andrew Spiegal
Fabio Fachin
Pascal Touchon
Paul Rennert
Steve Shamah
Bryan Choi, M.D.
Ran Reshef
Haro Hartounian
Jeffrey Miller
James Trager
Alex Franzusoff
Roman Yelensky
Marcelo Pasquini
Matthew Hewitt
Andrew Spiegal
Jennifer Malin
Friedrich Graf Finckenstein
Alice Brown
Zonghai Li
Stefan Wildt
Hans Klingemann
Dr Robert Hariri
Dan Shoemaker
Robert Tighe
Alan Trounson
David Martin
Hans Brok
Dr. Maria Fardis
Dr. Maria Fardis joined Iovance Biotherapeutics as President and Chief Executive Officer and was appointed to the Board of Directors in 2016. Since joining, the Company has been transformed from an early-stage development company to a company with multiple late-stage programs involving lifileucel and LN-145 for treatment of multiple solid tumors. Dr. Fardis served as the Chief Operating Officer of Acerta Pharma B.V., a clinical-stage biopharmaceutical company, from January 2015 to March 2016, where she worked on the development of Calquence® until the company’s acquisition by AstraZeneca. From 2011 to 2014, she worked at Pharmacyclics, Inc., where she was a key contributor in the creation of a broad clinical program leading to global approvals for Imbruvica® in multiple hematologic malignancies, and where she served as Chief of Oncology Operations and Alliances. Prior to joining Pharmacyclics, from August 2001 to April 2011, Dr. Fardis held increasingly senior positions in Medicinal Chemistry and the project and portfolio management department at Gilead Sciences, Inc., where she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of Letairis®. Dr. Fardis received her Ph.D. in Organic Chemistry from the University of California, Berkeley and her B.S. summa cum laude, in chemistry from the University of Illinois, Urbana-Champaign. Dr. Fardis holds an M.B.A., with highest honors, from Golden Gate University.
Headline Partner
EY Health Sciences and Wellness
Website: www.ey.com
The rise of the empowered consumer, coupled with technology advancements and the emergence of digitally focused entrants, is changing every aspect of health and care delivery. To retain relevancy in today’s digitally focused, data-infused ecosystem, all participants in health care today must rethink their business practices, including capital strategy, partnering and the creation of patient-centric operating models.
The EY Health Sciences and Wellness architecture brings together a worldwide network of 28,000 professionals to build data-centric approaches to customer engagement and improved outcomes. We help our clients deliver on their strategic goals; design optimized operating models; and form the right partnerships so they may thrive today and succeed in the health systems of tomorrow. We work across the ecosystem to understand the implications of today’s trends, proactively finding solutions to business issues and to seize the upside of disruption in this transformative age.
Platinum Partners
Miltenyi Biotec
Website: www.miltenyibiotec.com
At Miltenyi Biotec, we are committed to enabling the delivery of new cell and gene therapy (CGT) treatment options to patients with unmet medical needs. We develop tailored cell processing protocols for our GMP-compliant cell processing platform, the CliniMACS Prodigy®, to enable fully closed and automated manufacturing of complex CGT products. In addition, we offer contract development and GMP manufacturing of CGT products as well as design, development, and production of tailored GMP lentiviral vectors
Gold Partners
Avectas
Website: www.avectas.com
Company description: Avectas is a cell engineering business developing a unique delivery technology platform to enable the ex-vivo manufacture of our partners' gene modified cell therapy products, which will retain high in-vivo functionality. Avectas’ technology, Solupore®, delivers advanced molecules such as DNA, mRNA, proteins and gene editing tools to a range of primary cell types including T cells and NK cells for immuno-oncology and gene editing applications. We seek cell therapeutic developers to partner in the development of next-generation cell therapies using our Solupore non-viral delivery platform.
PHC Corporation of North America
Website: www.phchd.com/us/biomedical/about-us
PHC Corporation of North America is a subsidiary of PHC Holdings Corporation, Tokyo, Japan, a global leader in development, design and manufacturing of laboratory equipment for biopharmaceutical, life sciences, academic, healthcare and government markets. Following the close of the recent acquisitions of the anatomical pathology business from Thermo Fisher Scientific (currently operating as Epredia) and LSI Medience from Life Science Institute, Inc., PHC Group is now in the next transformative phase of its development.
nanoString
Website: https://www.nanostring.com/
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research and cited in 1,000+ peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System. The company is committed to offering tools that enable scientists and clinicians to translate today’s leading genomic research into clinically actionable tests that improve patient care. Gene expression panels for immune- oncology, autoimmunity, CAR-T and other applications are ready off the shelf tools offered to the Nanostring customers.
VIVEbiotech
Website: https://www.vivebiotech.com/
VIVEbiotech is a GMP CDMO fully focused on the development and GMP manufacture of lentiviral vectors from very early stages (even scratch) to GMP.
Being fully focused on customers´ projects, VIVEbiotech adapts to their requirements being highly flexible in terms of technical adaptation and slots availability.
VIVEbiotech is currently working for clients based in Europe, USA and Asia, manufacturing lentiviral vectors for different applications such as rare diseases as well as immune-oncology (CAR-Ts, TCRs, CAR-NKs, TILs), among others.
One of VIVEbiotech´s main features is our specialization in virology. Based on it, our R&D department is focusing its efforts on the development of more cost-effective processes and safer lentiviral vectors (worldwide patented technology called Lentisoma).
Event Partners
AllCells
Website: www.allcells.com
AllCells, for 21 years is the leader in providing high quality, economical blood & marrow-derived cells used by global researchers and bio-manufacturing organizations to develop cell therapies, vaccines, and therapeutics to treat cancer, infectious disease, and autoimmune disease. AllCells sources through our on-site, IRB-approved state-of-the-art donor facilities, where we collect cells and whole tissue from a large repository of recallable donors which enables custom orders to be fulfilled in the shortest time in the industry. We immediately process fresh tissue in our adjacent labs to produce purified cell types having unparalleled quality and consistency. Ask us about AllCells GMP Compliant Allogeneic Clinical Grade Products.
CellGenix
Website: www.cellgenix.com
CellGenix is a leading global supplier of high quality reagents and tools in the expanding market of cell and gene therapy and regenerative medicine.
As the first company to obtain a GMP manufacturing authorization for cell processing in Europe, CellGenix has more than 20 years of expertise in the development and GMP manufacturing of cell therapy products. Our products are used worldwide in clinical trials by academia and industry partners.
To ensure a seamless transition from research to commercialization we offer our customers a comprehensive product portfolio together with expert regulatory and technical support. Included in our product portfolio are cytokines, serum-free media and closed cell culture systems. Our products combine a maximum of quality and safety with excellent performance due to the state-of-the-art production, stringent in-house quality control and comprehensive documentation. All these factors help to simplify qualification and validation for your market authorization.
CellGenix operates a state-of-the-art GMP facility for production of recombinant proteins and cell processing in Freiburg, Germany. A subsidiary is located near Boston in Portsmouth, NH/USA.
KBI Biopharma
Website: https://www.kbibiopharma.com/
KBI Biopharma, Inc. is a biopharmaceutical Contract Development and Manufacturing Organization that accelerates the development of innovative discoveries into life-changing biological products. From early-stage to academic/non-profit organizations, to many of the world’s largest pharmaceutical companies, KBI has served 250+ clients globally to accelerate and optimize their drug development programs.
KBI’s extensive track record of successful programs is a result of its unique approach: applying the insight gained from our advanced biophysical and analytical characterization techniques toward the development of robust and scalable processes. KBI delivers accelerated and integrated process development and cGMP manufacturing programs for a wide range of recombinant protein Active Pharmaceutical Ingredients (API) and cell therapy products for our clients. KBI was founded in 1996 and operates 3 manufacturing facilities: Durham (NC), Boulder (CO), and The Woodlands (TX).
PeproTech
Website: www.peprotech.com
P=eproTech creates the building blocks of your life science research by manufacturing high-quality products that advance scientific discovery and human health. Since 1988, PeproTech has grown into a global enterprise manufacturing an extensive line of Recombinant Human, Murine and Rat Cytokines, Animal-Free Recombinant Cytokines, Monoclonal Antibodies, Affinity Purified Polyclonal Antibodies, Affinity Purified Biotinylated Polyclonal Antibodies, ELISA Development Kits, Cell Culture Media Products and GMP Cytokines
GenScript Biotech
Website: https://www.genscript.com/
GenScript Biotech is the world leader in biotechnology reagent service industry. Established in 2002 in New Jersey, United States, the company was the first to commercialize gene synthesis and successfully establish fully integrated capabilities for custom peptide synthesis, protein expression and engineering, custom antibody development and engineering, animal model development, in vitro/in vivo pharmacology as well as a variety of catalogue products, industrial enzymes and microbial reagents.
QuickSTAT
Website: www.quickstat.aero
For 40 years, the Quick Group has been serving the life science and healthcare community worldwide, providing 24/7 priority logistics and transportation solutions for time and temperature-sensitive, mission-critical and life-saving needs.
Our specially trained life science team, with unmatched experience, provides innovative and best in class logistics solutions for cell and gene therapies that ensure regulatory compliance, product integrity and patient safety.
With a global network, Quick can expedite delivery to anywhere in the world -- even to the most remote locations. We provide consultation on regulatory compliance, classification, import/export documentation and Dangerous Goods.
Our temperature control experts provide consultation and procurement of the latest packaging solutions for all temperature ranges, GPS tracking and temperature-monitoring devices, ensuring product integrity and patient safety. Whether your shipments need to remain at Controlled Room Temperature, 2 to 8ºC, or cryo frozen, Quick will handle your shipments utilizing certified GDP and quality processes.
Quick’s market leading technology, QuickOnlineRX, provides comprehensive management of your supply chain logistics, with real-time tracking and status alerts, and is fully scalable to meet the requirements of newly commercialized products.
As the trusted leader in personalized medicine logistics and transportation, Quick provides customized solutions and protocols to ensure the safety and integrity of your CAR-T Therapies. We’ll help you plan, design and support your logistics operation, so you can focus on your core business - creating cutting-edge healthcare treatments.
Roche Custom Biotech
Website: https://custombiotech.roche.com/
You are driving a paradigm shift. Scientific and technological advances emerging from creative companies across the globe are transforming the way we look at disease and breaking down boundaries for treatment. Now more than ever, business success hinges on working with advisors and suppliers who understand your needs and allow you to focus on what matters most.
What if all of those needs were met by a single partner — a market leader with decades of experience in biotechnology and in vitro diagnostics?
Introducing Roche CustomBiotech.
Leveraging the unique know-how of Roche Diagnostics and Roche Pharmaceuticals, we work with you to deliver high quality raw materials, instrumentation, products and services for your biopharmaceutical, cell therapy, or in vitro diagnostics business, customized to your unique quality and regulatory needs.
Avance Biosciences
Website: www.avancebio.com
Avance Biosciences is a leading CRO providing GLP/GMP-compliant assay development, assay validation, and sample testing services to support biological drug development and manufacturing activities world-wide.
We provide customized solutions for CAR T-cell therapy testing including: integration site analysis by NGS and Southern blot, preclinical QPCR biodistribution studies, preclinical QPCR quantification of mRNA from animal tissues, copy number analysis by QPCR or ddPCR, replication competent lentivirus (RCL) detection by QPCR, and testing of DNA or mRNA in clinical trial human samples.
When you partner with Avance Biosciences, we give you undivided attention, share our experience and knowledge, and respond to your needs in a timely manner. Contact our technical staff to discuss how we can support you in your project!
GBP Scientific
Website: https://gpbscientific.com/
Who we are
GPB Scientific is a pioneering biomedical company that works with leading research institutes and universities to develop breakthrough technologies that Get People Better. Since 2002, GPB has been at the forefront of microfluidics and cell biology for diagnostic and therapeutic applications. With offices and laboratories on both coasts, GPB has a long entrepreneurial track record of fostering breakthrough biomedical products and moving them into the commercial healthcare and diagnostic marketplace.
Our vision
GPB Scientific is a fusion of science and entrepreneurism driven by a spirit of the possible. Our work focuses on incubating exciting biomedical research, validating its promise and moving it into the marketplace where it can make a profound difference in people’s lives. Our vision is to get people better by accelerating the availability of pioneering science within the healthcare system.
Novartis
Website: www.novartis.com
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com
Cryoport
Website: www.cryoport.com
Cryoport is the life sciences industry's most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport also provides a range of bioservices to the life sciences industry, including biostorage for biological specimens, materials and samples. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal® Logistics Management Platform, leading-edge Smartpak II® Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts. Cryoport is dedicated to: simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting; delivering the most advanced temperature-controlled logistics solutions for the life sciences industry; and providing vital information that provides peace of mind throughout the life of each logistics process.
Werum IT Solutions
Website: https://www.werum.com
Werum IT Solutions is the world’s leading supplier of manufacturing execution systems (MES) and manufacturing IT solutions for the pharmaceutical and biopharmaceutical industries. Our out-of-the-box PAS-X software product is run by the majority of the world’s top 30 pharmaceutical and biotech companies but also by many mid-sized manufacturers.
Werum’s manufacturing IT solutions help pharma manufacturers to increase efficiency, improve productivity, and meet regulatory requirements. The range of projects includes global MES programs with multi-site rollouts all over the world as well as single-site solutions in individual countries.
Founded in 1969, Werum is headquartered in Lüneburg, Germany, and has many locations in Europe, America, and Asia.
Cytiva
Website: www.cytiva.com
Cytiva is a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics. Previously GE Healthcare Life Sciences, Cytiva’s diverse portfolio includes well-recognized brands such as ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Whatman and Xcellerex. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the delivery of transformative medicines to patients.
Visit cytiva.com for more.
Terumo BCT
Website: https://www.terumobct.com/cell-therapy-technologies
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular therapy technologies, believes in the potential of blood and cells to do even more for patients than they do today. Terumo BCT’s Cell Therapy Technologies business enables researchers, developers and manufacturers to create next-generation cell and gene therapies.
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
Poster Submission
Looking to showcase your recent work to the cell therapy community?
Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum, you need to be registered as a delegate. Please note that there are 20 assigned spaces for the Onco Cell Therapy Summit. Poster space is assigned on a first-come, first-served basis (subject to checks and successful registration).
At the Congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the afternoon networking break on day one.
Poster abstract submission deadline is on June 26th, 2020. Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!
Posters should be sized A0 (841mm x 1189mm) in portrait orientation.
For more information please contact [email protected]
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
